Abstract:Abstract Background: The complex and dynamic nature of the tumor-immune microenvironment presents challenges for identification of robust and predictive biomarkers in immuno-oncology (IO). Multiplex immunohistochemistry (mIHC) facilitates the ability to detect, phenotype, and quantify spatial relationships of cells within the tumor microenvironment (TME). Gene expression profiling allows for sensitive and high-throughput analysis of genes and signatures associated with the tumor, the immune response, and the TME, allowing examination of tumor-immune cell interactions. We used these approaches to generate multiple data sets from a cohort of HNSCC tumors and evaluated the correlation of the various analyte detection methods. These complementary technologies provide useful tools in the IO biomarker toolkit. Methods: Formalin-fixed paraffin-embedded (FFPE) specimens from HNSCC patients were cut into 5µm sections for all technologies. Multiplex fluorescent IHC was performed for TME markers CD3, CD8, PD-L1, PD1, CD68, Granzyme B, Ki67, and panCK/SOX10. Visualization and data analysis were performed with an Akoya Vectra Polaris and Akoya inForm and HALO software (Indica Labs). Data analysis included cell identification, phenotyping, spatial relationships, and quantitative digital pathology. Gene expression for 770 genes was performed utilizing the NanoString PanCancer IO 360 Gene Expression Panel. Transcripts were quantitated using a NanoString nCounter and target gene counts were normalized to internal housekeeping genes. Results: Analysis of the multiplex fluorescent IHC indicated a range of expression for the assayed TME biomarkers for the different tumor samples. Quantitative analysis of mIHC phenotype counts and normalized RNA counts for the targets contained in the antibody panel revealed a significant correlation between the analytic methods. Comparison of mIHC phenotype counts with a previously validated IO gene signature containing a broader set of IO-relevant genes, the Tumor Information Signature, (Ayers, et al., J Clin Invest. 2017; 127:2930) also showed a correlation. Conclusions: The technologies described above enable the investigation of the TME for use in biomarker discovery, drug discovery, and IO pathway interrogation. These technologies can be used in parallel to uncover roles in the biomarker discovery pathway for genes of interest. The combination of mIHC and gene expression panels can be used to screen a broad range of targets, that then can be further investigated using the spatial analysis capabilities of mIHC to gain greater insight into the immune infiltrate density at any singular area of the TME. Citation Format: Carlee Hemphill, Timothy Maynor, John Bauman, Caitlin Schroyer, Jeffery Shuster, Thomas Turi, Steven M. Anderson. Multiplex immunohistochemistry, spatial analysis, and gene expression profiling of the tumor-immune microenvironment in HNSCC tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2637.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma

Validation of an Accurate Automated Multiplex Immunofluorescence Method for Immuno-Profiling Melanoma

Multiplexed Imaging Mass Cytometry Reveals Distinct Tumor-Immune Microenvironments Linked to Immunotherapy Responses in Melanoma

Quantitative multiplex immunohistochemistry reveals inter-patient lymphovascular and immune heterogeneity in primary cutaneous melanoma

Spatially mapping the immune landscape of melanoma using imaging mass cytometry

Bright-Field Multiplex Immunohistochemistry Assay for Tumor Microenvironment Evaluation in Melanoma Tissues

Multiplex Immunohistochemistry for Mapping the Tumor Microenvironment

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma

Spatial assessment of stromal B cell aggregates predicts response to checkpoint inhibitors in unresectable melanoma

Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment

Mapping the single cell spatial immune landscapes of the melanoma microenvironment

Multiplex Immunohistochemistry and High-Throughput Image Analysis for Evaluation of Spatial Tumor Immune Cell Markers in Human Breast Cancer.

Abstract 2637: Multiplex immunohistochemistry, spatial analysis, and gene expression profiling of the tumor-immune microenvironment in HNSCC tumors

Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer

Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma

In-Depth Immune-Oncology Studies of the Tumor Microenvironment in a Humanized Melanoma Mouse Model

Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment

Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients

Dual PD-L1/SOX10 Immunohistochemistry Combined With Digital Imaging Enhances Stratification Accuracy of Patients With Metastatic Melanoma

Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden